Navigation Links
Cambridge Laboratories Announces Approval of Tetrabenazine in Spain
Date:12/8/2008

DUBLIN and NEWCASTLE, England, December 8 /PRNewswire/ --

- Marketing Partner UCB Expects to Receive Completed Price and Reimbursement Approval for Tetrabenazine in H1 2009

- Exclusive Distribution Rights Granted in Finland (MediFront) and Taiwan (Giddi Pharma); Distribution Contracts Renewed in Australia and New Zealand

Cambridge Laboratories Limited ("Cambridge" or "the Company"), the privately-owned specialty pharmaceutical company, today announces that its flagship product Tetrabenazine, (known as NITOMAN(R) in Germany and other key European territories and XENAZINE(R) in the UK, US and other markets) has received marketing approval in Spain from the Agencia Espanola de Medicamentos y Productos Sanitarios.

The Company also announces that it has recently signed distribution agreements for Tetrabenazine in Finland and Taiwan, and renewed existing arrangements in Australia and New Zealand.

Tetrabenazine will be marketed as NITOMAN(R) in Spain by Cambridge's marketing partner UCB upon successful completion of all related procedures. It has been approved for the treatment of movement disorders associated with Huntington's disease, a condition for which there is major unmet medical need.

Cambridge has recently renegotiated its agreements with UCB in Spain and Portugal, giving UCB ten year exclusive marketing rights to Tetrabenazine in Spain. UCB, a global biopharmaceutical company, is focused on severe diseases in three therapeutic areas - inflammation, oncology and neurology. The renegotiated terms follow UCB's acquisition of Celltech, Cambridge's former partner in Spain and Portugal, and the more recent merger of UCB with Schwarz Pharma.

UCB is currently in the process of applying for price and reimbursement in Spain and expects to have this procedure completed in the first half of 2009.

Mark Evans, CEO of Cambridge, said: "The granting of a
'/>"/>

SOURCE Cambridge Laboratories Limited
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters
2. IBT Laboratories Expands its Menu of Tests for Immune Deficiency
3. Roxane Laboratories, Inc. Updated Launch of Calcium Acetate Capsules, 667mg
4. Forest Laboratories, Inc. and Gedeon Richter Plc Announce Positive Phase II Results with the Investigational Antipsychotic Cariprazine in Patients with Acute Mania Associated with Bipolar I Disorder
5. Forest Laboratories Announces Positive Results from Phase III Clinical Studies of Ceftaroline for the Treatment of Complicated Skin and Skin Structure Infections
6. Romark Laboratories Completes Enrollment in U.S. Phase II Study of Nitazoxanide for Chronic Hepatitis C Genotype 1 Non-Responders
7. Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results
8. Northfield Laboratories Inc. Presentation at FDA/NIH Workshop on Hemoglobin-Based Oxygen Carriers
9. Romark Laboratories Initiates Phase II Study of Nitazoxanide in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1
10. Microbia and Forest Laboratories Announce Preliminary Results of Linaclotide Phase 2b Studies
11. Romark Laboratories Raises $18 Million in Institutional Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... July 29, 2014 New high priced hepatitis ... D by a projected $2.9 to $5.8 billion next ... firm Milliman released today by the Pharmaceutical Care Management ... could increase by as much as 8.6 percent in ... including Sovaldi and Olysio. The study finds ...
(Date:7/29/2014)... July, 29  2014 ISPE—the International Society for ... John Bournas as President and CEO, succeeding ... leave the Society last fall.  Mr. Bournas takes ... the healthcare association industry as well as significant ... clear vision for the expansion of its global ...
(Date:7/29/2014)... July 29, 2014 /PRNewswire-iReach/ -- MHG Medical Management ... launched its Medical Equipment and X-ray Annual ... are tailored to the cruise industry,s unique requirements.  ... operators to propose that they should develop a ... program is intended to create standardized processes and ...
Breaking Medicine Technology:New Milliman Study: Hepatitis C Drugs Could Increase Medicare Part D Spending by $2.9 to $5.8 Billion in 2015 2ISPE Hires Healthcare Association Exec as CEO 2ISPE Hires Healthcare Association Exec as CEO 3MHG Medical Management Services Aims to Change Cruise Industry Standard With New Equipment Maintenance Program 2
... (NYSE: WPI ), a leading specialty global ... and Chief Executive Officer, will provide an overview and ... Bernstein 28th Annual Strategic Decisions Conference on Wednesday, May ... Hotel in New York, New York.  The presentation will ...
...  Perrigo Company (Nasdaq: PRGO;TASE) today announced that it has ... Administration for its abbreviated new drug application (ANDA) for ... have already begun.  (Logo: http://photos.prnewswire.com/prnh/20120301/DE62255LOGO ... U.S. store brand market is bioequivalent to Novartis, Prevacid® ...
Cached Medicine Technology:Watson to Present at the Sanford C. Bernstein 28th Annual Strategic Decisions Conference 2Perrigo Announces FDA Final Approval and Launch of Store Brand OTC Lansoprazole 15mg Capsules 2
(Date:7/30/2014)... With the accelerated aging of the ... as well as the improved medical care facilities ... industry has been developing quickly, especially in vitro ... in vitro diagnostics market size reached RMB22.98 billion, ... diagnostic reagents. , Chinese in vitro diagnostic ...
(Date:7/30/2014)... Angeles, California (PRWEB) July 30, 2014 ... an online dating community where motorcycle enthusiasts congregate, ... on the site that were revealed by BikerKiss indicate ... increase in the past 3 years. , Members on ... US, UK, Canada, Australia and some other European countries ...
(Date:7/30/2014)... WA (PRWEB) July 30, 2014 According to ... Vkool.com, this is a comprehensive bodybuilding guide for men who ... by up to 50 pounds in within a few ... that will help keep their shoulders healthy and avoid the ... the Critical Bench Program 2.0 uncovers to learners the reason ...
(Date:7/30/2014)... San Diego, CA (PRWEB) July 30, 2014 ... of Melinda J. Helbock A.P.C. are announcing that they are ... from the negative effects of asbestos exposure. , “Symptoms ... that were exposed to the toxin 30 plus years ago ... Melinda Helbock, Founder of The Law Office of Melinda J. ...
(Date:7/30/2014)... TN (PRWEB) July 30, 2014 Regents ... medical imaging services, has brought health care industry veteran ... on board to help lead the company’s ambitious plans ... , “Regents Health has been moving along at a ... to kick it up a notch,” says Bob Maier, ...
Breaking Medicine News(10 mins):Health News:China Diagnostic Reagent Industry (biochemical, molecular & immunodiagnostic) 2016 Forecasts in New Research Report at ChinaMarketResearchReports.com 2Health News:China Diagnostic Reagent Industry (biochemical, molecular & immunodiagnostic) 2016 Forecasts in New Research Report at ChinaMarketResearchReports.com 3Health News:China Diagnostic Reagent Industry (biochemical, molecular & immunodiagnostic) 2016 Forecasts in New Research Report at ChinaMarketResearchReports.com 4Health News:Single Women Motorcycle Riders In Rapid Increase 2Health News:The Critical Bench Program 2.0 Pdf Review Exposes Mike Westerdal's Guide for Increasing Bench Press – Vkool.com 2Health News:The Critical Bench Program 2.0 Pdf Review Exposes Mike Westerdal's Guide for Increasing Bench Press – Vkool.com 3Health News:The Law Office of Melinda J. Helbock A.P.C. Offers Case Evaluations for Possible Asbestos Claims 2Health News:Sferrella and Demonbreun Join Regents Health Resources 2
... the long-term consequences of too much sun exposure can be ... anyone who's spent a day basking on the beach. ,Characterized ... to the touch, sunburn is a sure, almost immediate sign ... been damaged by the sun's ultraviolet rays. And the consequences ...
... havoc on a woman’s bones and a new study reveals ... Researchers know bone loss occurs after menopause, increasing chances of ... and strength. ,The Swedish study involved 146 women who were ... done to determine bone size and density. //All fractures related ...
... week may cut their risk of Alzheimer's by more than ... that diet may affect a person's chances of developing the ... that people 65 and older who had fish once a ... those who never or rarely ate fish. The meals included ...
... you don't use your mind regularly through activities such ... you risk losing some of your cognitive abilities as ... appearing in the June 19 issue of the New ... of Medicine in New York City found seniors who ...
... Clinic in Rochester, Minn., say they have found a ... is an allergic inflammatory reaction of the esophagus. The ... research shows a topical corticosteroid therapy is effective for ... of high levels of eosinophils. Eosinophils are a type ...
... women with colon cancer that has advanced beyond the ... outcome, according to a recent study. In addition to ... may have an increased risk of cancer recurrence, at ... long-term outcomes and treatment-related side effects in colon cancer ...
Cached Medicine News:
Molt periosteal elevator #9, 18.5 cm, 7-1/4"....
Periosteal elevator #9, 18 cm, 7"....
Full curve periosteal elevator - cervical - sharp, round tip, length 184 mm (7 1/4")....
... The Frontier Anterior Deformity System ... Kass, Moss Miami, and Isola ... thoracoscopic procedures to deliver unsurpassed versatility, ... the highest level of versatility for ...
Medicine Products: